JB Pharma is riding the CDMO Opportunity. Jefferies reiterates buy…

Jefferies maintains a Buy rating on JB Pharma with a revised target price of Rs 2,310, citing intact growth drivers and a strong CDMO business recovery. Q3 earnings showed a 33% YoY growth in CDMO sales, expected to pick up in Q4FY25. Management expects steady India sales and plans to repay debt, with strong execution […]